Sitagliptin

Generic Name
Sitagliptin
Brand Names
Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
Drug Type
Small Molecule
Chemical Formula
C16H15F6N5O
CAS Number
486460-32-6
Unique Ingredient Identifier
QFP0P1DV7Z
Background

Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.

Indication

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.

It is also used in combination with metformin or ertugliflozin.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News

Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant

Phase 4
Completed
Conditions
Pancreatitis
Diabetes
Interventions
Drug: Placebo
Drug: Sitagliptin
First Posted Date
2010-08-23
Last Posted Date
2017-05-31
Lead Sponsor
University of Minnesota
Target Recruit Count
83
Registration Number
NCT01186562
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

START-J: SiTAgliptin in eldeRly Trial in Japan

Not Applicable
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Sitagliptin
Drug: Glimepiride
First Posted Date
2010-08-17
Last Posted Date
2017-04-14
Lead Sponsor
Japan Association for Diabetes Education and Care
Target Recruit Count
305
Registration Number
NCT01183104
Locations
🇯🇵

Japan Association for Diabetes Education and Care, Chiyoda-Ku, Tokyo, Japan

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

First Posted Date
2010-08-09
Last Posted Date
2014-06-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
986
Registration Number
NCT01177813
Locations
🇧🇪

1245.20.32016 Boehringer Ingelheim Investigational Site, Deurne, Belgium

🇺🇸

1245.20.10154 Boehringer Ingelheim Investigational Site, Chino, California, United States

🇺🇸

1245.20.10078 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States

and more 121 locations

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

Phase 2
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: SK-0403
Drug: Placebo
Drug: Sitagliptin
First Posted Date
2010-07-23
Last Posted Date
2011-08-17
Lead Sponsor
Kowa Research Institute, Inc.
Target Recruit Count
620
Registration Number
NCT01169090

Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)

Phase 1
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: Insulin
Drug: sitagliptin
First Posted Date
2010-07-12
Last Posted Date
2018-07-31
Lead Sponsor
European Foundation for the Study of Diabetes
Target Recruit Count
30
Registration Number
NCT01159847
Locations
🇨🇳

Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

First Posted Date
2010-05-24
Last Posted Date
2017-10-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
66
Registration Number
NCT01128621
Locations
🇺🇸

GSK Investigational Site, Miami, Florida, United States

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

First Posted Date
2010-05-10
Last Posted Date
2018-01-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
100
Registration Number
NCT01119846
Locations
🇺🇸

GSK Investigational Site, Tacoma, Washington, United States

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: Sitagliptin
Drug: atorvastatin
First Posted Date
2010-04-28
Last Posted Date
2013-01-24
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
33
Registration Number
NCT01112670
Locations
🇺🇸

University of Colorado Denver, Aurora, Colorado, United States

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

First Posted Date
2010-04-20
Last Posted Date
2013-07-15
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
344
Registration Number
NCT01106690

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

First Posted Date
2010-04-20
Last Posted Date
2013-07-30
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
1284
Registration Number
NCT01106677
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy